This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
by Zacks Equity Research
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
by Zacks Equity Research
Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.
Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PRFZ
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
by Zacks Equity Research
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 0% and 2.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PRFZ
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 4.35% and 3.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
by Zacks Equity Research
Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
by Zacks Equity Research
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.
Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
Here's Why You Should Retain Prestige Consumer (PBH) Stock Now
by Zacks Equity Research
The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
by Zacks Equity Research
ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today
by Zacks Equity Research
Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.